
Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).


